Skip to Content
Merck
CN

Key Documents

View All Documentation

P6402

Perphenazine

Synonym(s):

4-[3-(2-Chloro-10H-phenothiazin-10-yl)propyl]-1-piperazineethanol

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View

About This Item

Empirical Formula (Hill Notation):
C21H26ClN3OS
CAS Number:
58-39-9
Molecular Weight:
403.97
NACRES:
NA.77
PubChem Substance ID:
24278642
UNSPSC Code:
12352200
EC Number:
200-381-5
MDL number:
MFCD00056798
Form:
powder
Quality level:
200
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

form

powder

Quality Level

200

originator

Schering Plough

storage temp.

2-8°C

SMILES string

ClC(C=C1)=CC2=C1SC3=CC=CC=C3N2CCCN4CCN(CCO)CC4

InChI

1S/C21H26ClN3OS/c22-17-6-7-21-19(16-17)25(18-4-1-2-5-20(18)27-21)9-3-8-23-10-12-24(13-11-23)14-15-26/h1-2,4-7,16,26H,3,8-15H2

InChI key

RGCVKNLCSQQDEP-UHFFFAOYSA-N

Gene Information

human ... ADRA1A(148), ADRA1B(147), ADRA1D(146), ADRA2A(150), ADRA2B(151), ADRA2C(152), DRD2(1813), OPRS1(10280)

General description

Perphenazine is an antipsychotic drug used in treating schizophrenia. It modulates antioxidant levels and helps in the management of oxidative injury in schizophrenia. However, it is less effective than the clozapine drug group in improving response to oxidative injury.

Biochem/physiol Actions

D2 dopamine receptor antagonist; α-adrenergic receptor antagonist and σ-receptor agonist; phenothiazine antipsychotic. Inhibits glutamate dehydrogenase in vitro.

Features and Benefits

This compound was developed by Schering Plough. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Still not finding the right product?

Explore all of our products under Perphenazine

pictograms

Exclamation mark
GHS07

signalword

Warning

hcodes

H302,H317

Hazard Classifications

Acute Tox. 4 Oral - Skin Sens. 1

Storage Class

11 - Combustible Solids

wgk

WGK 3

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
MKCP4160
MKCN2541
MKCL7843
MKCJ3437
MKCG6835

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Articles

许多癌细胞中的谷氨酰胺代谢失调

本文介绍了增殖活性细胞为何需要碳源和氮源合成大分子。尽管大部分肿瘤细胞利用有氧糖酵解途径并分流线粒体氧化磷酸化代谢物，但许多肿瘤细胞表现出线粒体活性增加。

Glutamine Metabolism in Cancer Cells

Sigma article discusses tumor cell metabolic pathways, focusing on aerobic glycolysis and mitochondrial activity.

Angela M Koranek et al.
Schizophrenia research, 137(1-3), 137-140 (2012-03-01)
Results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) indicate that, with the exception of olanzapine, no substantial overall differences were identified between second generation antipsychotics (SGAs) and the first generation antipsychotic (FGA) perphenazine. This study evaluated the effect
J Nordenberg et al.
Biochemical pharmacology, 58(8), 1229-1236 (1999-09-16)
Some of the psychotropic agents widely used for the amelioration of anxiety, depression, and psychosis also show an effect at the cellular proliferation level. Surprisingly little research, however, has been directed to the antitumoral potential of these drugs, alone or
Frank B Yoon et al.
Statistics in medicine, 30(16), 1917-1932 (2011-05-04)
In clinical trials multiple outcomes are often used to assess treatment interventions. This paper presents an evaluation of likelihood-based methods for jointly testing treatment effects in clinical trials with multiple continuous outcomes. Specifically, we compare the power of joint tests
View All Related Papers

Global Trade Item Number

SKUGTIN
P6402-5G04061832092775
P6402-1G04061834393320